8:10–8:30

Abstract 10506

A phase 2 study of ponatinib in patients (pts)   with advanced gastrointestinal stromal tumors (GIST) after failure of   tyrosine kinase inhibitor (TKI) therapy: Initial report.

普纳替尼（ponatinib）治疗酪氨酸激酶抑制剂（TKI）失败后的进展期胃肠间质瘤（GIST）的II期临床研究初步报告。

杨  林(Lin Yang)

Abstract 10508

Long-term disease control of   advanced gastrointestinal stromal tumors (GIST) with imatinib (IM): 10-year   outcomes from SWOG phase III intergroup trial S0033.

伊马替尼（IM）在进展期胃肠道间质瘤（GIST）中的长期疾病控制：来自于西南肿瘤协作组（SWOG）的III期临床试验S0033的十年结果。

8:30–8:45

专家评述

Discussion Topic: What happen to GIST after 12 years of targeted   therapy

讨论主题：靶向治疗胃肠道间质瘤（GIST）十二年后现状

龙浩锋

(Herbert Ho-Fung Loong)

翻译：樊  英(Ying Fan)

8:45–8:50

讨论(Q &   A)

秦叔逵(Shu-Kui Qin)、

潘宏铭(Hong-Ming Pan)、龙浩锋

(Herbert   Ho-Fung Loong)